Ascendis Pharma to enter new disease area with eye disorder candidate
During an investor conference, the Danish biotech company presented plans to develop a treatment for wet age-related macular degeneration, wet AMD.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
Denmark-based biotech company Ascendis Pharma is training its sights on the market for treating eye disorders, and its first targeted indication is wet age-related macular degeneration, wet AMD.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA sets deadline for Ascendis Pharma drug decision
For subscribers
